The Healthcare Innovation Portfolio remains in the early build-out phase with two open positions: Doximity, Inc. (DOCS) and TransMedics Group, Inc. (TMDX). As of the stored quote history through June 16, 2026, DOCS is up 2.91% from its first quote and TMDX is up 0.45%. This is not yet a performance sample large enough to draw big conclusions, but the important point is that both names are behaving within the expected range for newly initiated healthcare technology positions.
Positioning: Two Different Forms of Healthcare Technology
The portfolio currently holds two complementary, but still U.S.-listed, healthcare innovation businesses. Doximity represents the digital workflow and clinician-network side of the theme. Its value proposition is tied to physician engagement, healthcare professional communication, medical marketing, and AI-enabled clinical productivity tools. Doximity reported fiscal 2026 revenue of $644.9 million, up 13% year over year, fiscal 2026 free cash flow of $317.5 million, and a record of more than 800,000 active prescribers using workflow tools in its fiscal fourth quarter. Management also guided fiscal 2027 revenue to $664 million to $676 million, implying a slower but still profitable growth profile. ([investors.doximity.com](https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fourth-Quarter-and-Fiscal-Year-2026-Financial-Results/default.aspx))
TransMedics gives the portfolio exposure to a different part of healthcare innovation: organ transplant technology, organ preservation, and transplant logistics. The company reported first-quarter 2026 revenue of $173.9 million, up 21% year over year, and reiterated full-year 2026 revenue guidance of $727 million to $757 million. Its business is not a software marketplace; it is a high-complexity medical technology and logistics platform built around the Organ Care System, the National OCS Program, aircraft capacity, and clinical expansion programs in heart, lung, liver, and eventually kidney transplantation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1756262/000119312526206347/tmdx-ex99_1.htm))
Performance Drivers This Week
DOCS has contributed the larger gain so far, helped by the market’s recognition that the company remains highly profitable and cash-generative even as revenue growth moderates. The current debate is not whether Doximity has a real platform; it is whether fiscal 2027 growth expectations are enough to justify renewed multiple expansion. At the latest checked market data, DOCS traded at $20.89, with a market capitalization near $4.16 billion and a reported P/E ratio of about 17.4.
TMDX is almost flat from entry, which is acceptable for a position initiated only this week. The market appears to be balancing strong top-line growth and a large addressable opportunity against near-term margin pressure from investment. In the first quarter of 2026, TransMedics reported that gross margin declined to 58% from 61% in the year-earlier period, while operating expenses rose as the company invested in research and development and broader growth infrastructure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1756262/000119312526206347/tmdx-ex99_1.htm)) At the latest checked market data, TMDX traded at $75.82, with a market capitalization near $2.74 billion.
Risk Concentration
The main portfolio risk is not yet single-stock losses; it is concentration and narrow thematic expression. With only two holdings, the portfolio is exposed to company-specific surprises: a Doximity advertising slowdown, weaker-than-expected uptake of AI workflow tools, TransMedics execution issues, margin pressure, aircraft/logistics costs, or clinical-program delays. Both companies are also U.S.-listed, even though the portfolio mandate is thematic and global. That is not a rule violation, because thematic portfolios should pursue the best global opportunity set without artificial exchange restrictions. However, it does mean the next additions should ideally broaden the opportunity set geographically and by business model.
From a factor perspective, DOCS is the more cash-rich, high-margin digital platform. TMDX is the more operationally complex medical technology growth company. That mix is healthy, but still incomplete. A more mature Healthcare Innovation Portfolio should eventually include several additional sleeves: diagnostics and testing platforms, AI-assisted clinical decision support, robotic or minimally invasive procedure technology, remote monitoring, healthcare cybersecurity, data interoperability, and select international medtech or digital-health leaders.
What We Are Watching Next
- Doximity: Watch whether fiscal 2027 guidance proves conservative, whether AI workflow engagement translates into paid revenue, and whether operating leverage stabilizes after heavier investment.
- TransMedics: Watch quarterly OCS case growth, liver and heart momentum, the pace of European National OCS Program expansion, margin recovery, aircraft utilization, and progress in the heart, lung, and kidney pipeline.
- Portfolio construction: Watch for opportunities to add a third or fourth healthcare technology position that reduces dependence on only two business models.
- Valuation discipline: Neither position should be chased blindly. Future additions should balance growth durability, balance-sheet quality, regulatory risk, and evidence of adoption.
Portfolio Decision: No Positions Closed
No positions are being closed this week. Both DOCS and TMDX are still inside the portfolio’s protected minimum holding-period discipline, and neither has shown a thesis break, catalyst failure, poor fit, liquidity problem, or valuation overextension that would justify overriding that discipline. The correct action is to keep both positions open, monitor the next earnings and guidance updates, and look for a high-quality third addition that diversifies the portfolio’s healthcare technology exposure.
Bottom line: The Healthcare Innovation Portfolio is positioned around two attractive healthcare technology vectors: digital clinician workflow through Doximity and organ transplant transformation through TransMedics. The early performance is positive, but the portfolio is still too concentrated to be considered fully built. Patience is warranted, and the next move should be diversification rather than premature selling.
Risk disclaimer: This article is for informational and educational purposes only and is not financial advice. Stocks in healthcare technology and medical innovation can be volatile and may be affected by regulation, reimbursement, clinical results, competition, execution risk, and broader market conditions. Investors should conduct their own research and consider their risk tolerance before making investment decisions.